1	High seroprevalence after the second wave of SARS-COV2 respiratory infection in a small
2	settlement on the northern coastal of Peru.

4	Angie K. Toledo <sup>1,2</sup> , Franco León-Jimenez <sup>3,4</sup> , Sofia Cavalcanti <sup>4</sup> , Percy Vilchez-Barreto <sup>5</sup> , Narcisa
5	Reto <sup>6</sup> , Jessica Vega <sup>7</sup> , Lucia M Bolivar <sup>8</sup> , Matilde Rhor <sup>9</sup> , Jhon Ypanaque <sup>9</sup> , Henry Silva <sup>9,10</sup> , and Luz
6	M. Moyano <sup>3*</sup> , Group of Neuroepidemiology and Science of Life of Peru.
7	
8	1. School of Public Health and Administration, Universidad Peruana Cayetano Heredia, Lima,

- 9 Peru
- 10 2. Centro de investigación para la preservación de la vida, Lima, Peru
- 11 3. Escuela de Medicina Humana, Universidad Cesar vallejo
- 12 4. Dirección de Investigación Hospital Amistad Perú-Korea Sta. Rosa II-2, Piura Peru
- 13 5. Centro de Salud Global, Universidad Peruana Cayetano Heredia, Tumbes, Peru
- 14 6. Hospital I Carlos Alberto Cortés Jiménez Essalud, Tumbes, Peru
- 15 7. Dirección ejecutiva de epidemiología (Chief), Centro de Salud Pampa Grande, Regional
- 16 Directorate of Health, Tumbes, Peru
- 17 8. Centro de Salud Pampa Grande, Regional Directorate of Health, Tumbes, Peru.
- 18 9. Psycology School (MR), Social and Cultural Office (JY), and Economy and Political Science
- 19 School (HS), Universidad Nacional de Tumbes, Tumbes, Peru
- 20 10. Unidad Médico legal II Tumbes, Instituto de Medicina Legal del Peru.
- 21
- 22 \* lmmoyanom@ucvvirtual.edu.pe (LMM)
- 23 Short title: Tumbes, Peru: High Covid-19 seroprevalence during second wave
- 24
- 25

26

27

# 28 Abstract

Background. Due to more infections from variations that could escape vaccination and immunity by asymptomatic to uninfected transmission, COVID-19's second wave had higher seroprevalence globally. Public health constraints and herd immunity may not work against these novel variations' infectivity. This population-based study in Peru's Tumbes Region during the second wave of COVID-19 seeks to determine seroprevalence and demographic changes from the first wave.

34 Methodology/Principal findings. In Dec 2021-Jan 2022, a study in Tumbes' informal settlement 35 sampled individuals over 2 years old from one in every four households. Finger-prick blood 36 samples and symptom surveys were collected. On the second wave, there was a substantial rise in 37 adjusted seroprevalence (50.15%, 95% CI [45.92 – 54.40]) compared with the first wave (24.82 %, 38 95%CI [22.49 – 27.25]), with females maintaining a higher seroprevalence (53.89; 95% CI [48.48-39 59.23]) vs. 45.49; 95% CI [38.98-52.12], p=0.042) compare to males. Those under 18 years of age 40 had the highest IgG seropositivity: the 12–17 age group during the second wave (85.14%) and the 41 2-11 age group (25.25%) during the first wave. Nasal congestion and cough were symptoms 42 associated with seropositivity, unlike the first wave.

43 Conclusions/Significance. In Tumbes, the seroprevalence of COVID-19 increased by twofold 44 compared to the initial wave. Inadequate infrastructure and limitations in human resources and 45 supplies in healthcare facilities made the Peruvian health system collapse. We must include in 46 epidemiological surveillance mHealth tools that enable real-time reporting of new cases. Working 47 alongside the community is the only way to improve any new intervention strategy to prevent or 48 control a new pandemic.

# 49 **Author summary**

50 In Peru, the healthcare system was overwhelmed by the COVID-19 pandemic due to the lack of 51 hospital capacity, oxygen supply, political unrest, and a fragmented healthcare system. During the 52 first wave, the prevalence ranged from 20.8% to 72%, and it was predicted that the second wave 53 would be disastrous. To assess the seroprevalence of SARS-CoV-2, a cross-sectional study was conducted in the settlement "AAHH Las Flores" located in front of Tumbes National University's 54 55 main campus. A door-to-door intervention was conducted, and a total of 580/781 (74.26%) 56 individuals over than 2 years and above agreed to participate. After adjusting for sensitivity and 57 specificity, the calculated adjusted seroprevalence was 50.15%. Women had a slightly higher 58 adjusted seroprevalence compared to men, and the age groups with the highest prevalence of IgG 59 seropositive were from 12 to 17 years, from 30 to 59 years, and older than 60 years. More than 80% 60 of seropositive patients were asymptomatic in all age groups. The study's findings suggest that 61 COVID-19 transmission in the settlement was higher during the second wave, and asymptomatic 62 individuals could have played a critical role in spreading the virus.

# 63 Introduction

64 Due to a lack of hospital capacity, critical oxygen supply, political unrest, and a fragmented healthcare system, Peru experienced high rates of morbidity and mortality during the first and 65 second catastrophic waves (1-3). Prevalence rates on the first wave ranged from 20.8% to 72% 66 67 (1,2,4,5). Without the option of massive vaccination, a disastrous second wave was expected unless 68 the health system responded adequately. On December 17th, 2021, in the Tumbes district, close to 69 93% of the population over 18 years old and seniors had received the first dose of the Sinopharm 70 and Pfizer COVID-19 vaccine. 75% of the population between the ages of 12 and 17 was 71 vaccinated, while no one under the age of 12 had been immunized (6). The first wave hit Peru in 72 March 2020, peaked in August, and declined in December 2020 (7). The second wave started in 73 January, with the highest number of infections and deaths decreasing in June 2021. Throughout a 74 significant portion of the second wave, the number of daily infections consistently exceeded the 75 number of daily recoveries. The peak was observed during week 54, specifically from March 22nd 76 to 28th, with an average of 9,079 new infections and 8,727 recoveries per day (8,9). The highest 77 attack rate (6.96) was for 30- to 59-year-olds, followed by 6.56 for adults aged 60 and above. (9). 78 During this same period, Tumbes had the seventh highest cumulative attack rate (5.29), compared 79 with the national average of 4.84. The Tumbes case fatality rate rose from 3.54% to 9.40% on 80 May's last day of 2021. Peru was fifth in the world for deaths per 100,000 people (10), behind the United States, Brazil, India, and Mexico (2,9). In April 2021, during the peak of cases, the Tumbes 81 82 region had three hospitals, 17 beds in the ICU, and 20 mechanical ventilators(11).

83

A cross-sectional study conducted in a rural village of Tumbes (Puerto Pizarro) during the final days of the first wave found an adjusted seroprevalence of 24.82% (12) where; with being a woman [28.03%, p=0.002], water storage [PR 1.37, p=0.034], and symptoms such as fever, general discomfort, cough, nasal congestion, respiratory distress, headache, anosmia, and ageusia being

variables associated with a positive antibody rapid-test of Sars-cov-2 (12,13). Taking full advantage of the regional program of active surveillance of the Tumbes Government (GORE) and Regional Directorate of Health (DIRESA) (14), we conducted a cross-sectional study in a human settlement named AAHH Las Flores (n = 781 population): a) to assess seroprevalence of SARS-CoV-2 at the end of the second wave, b) to determine distribution by age group, and health determinants associated with residents over 2 years old.

94

# 95 Materials and methods

# 96 Ethical considerations

97 Approval for the study protocol and consent forms was obtained from the institutional review 98 boards of Universidad Peruana Cayetano Heredia and the Regional Directorate of Health (DIRESA, 99 Spanish acronym) in Tumbes. To ensure comprehension, illiterate individuals were included by 100 having the IC and survey read aloud to them. All participants provided written informed consent 101 (IC) in the presence of a witness (S1 Text). For minors, both the minor and their parents or legal 102 guardians provided written informed consent (S2 Text).

103

# 104 Area and study population

105 The settlement "AAHH Las Flores," which has a population of 781 individuals, is located in the 106 Pampa Grande Population Center in the district and province of Tumbes. It is situated 2.5km away 107 from the town center and lacks proper infrastructure, with unpaved streets and no continuous access 108 to safe drinking water (15). The population is of a homogeneous mestizo ethnicity. According to the 109 last national census, the population of this settlement was 721 individuals, with a total of 184 100 households. Also, 94.5%, had access to potable water and 95.1% had access to sewage disposal 111 (16).

112 The Pampa Grande health facility was staffed by six physicians, six nurses, six midwives, one 113 pediatrician, and six nursing technicians. It provides 24/7 service and has an ambulance for 114 emergency transportation (17).

115

# 116 Study design and sampling

117 A cross-sectional analytical approach was used to invite and enroll individuals over than 2 years 118 and above (n=781 pop) through a door-to-door intervention conducted between December 2021 and 119 the first day of January 2022. This intervention took place after the second wave and a few weeks 120 before the start of the third wave.

121

122 The recruitment process, censuses, and rapid antibody testing for COVID-19, were described 123 elsewhere (12,13). Briefly, the regional directorate of Health-Tumbes and the Center for Global 124 Health collaborated to conduct a nominal census with block-numbered homes. Individuals over the 125 age of two who stayed in the village at least three nights per week and consented to sign the 126 informed consent form were eligible to participate. The study included 781 individuals who met 127 these criteria. Non-medical field workers collected blood samples via finger prick and explained the 128 results of the lateral flow test to everyone surveyed. Clinical signs suggestive of COVID-19 disease 129 were evaluated in accordance with WHO criteria (18). Trained physicians from the study team 130 evaluated participants with respiratory symptoms, and data was entered into the Notiweb and 131 SISCOVID databases for follow-up by the healthcare system. The COVID-19 Clinical 132 Epidemiological Investigation format was used to identify symptoms experienced within the 133 previous 14 days, as recommended by the Peruvian Ministry of Health (19).

134

A census previously validated by the Center for Global Health in epidemiological population-based
investigations was used in this study (20,21). Comorbidities were determined as the existence of at

137 least one of the following medical disorders: hypertension, diabetes, hepatic disease, renal disease,

138 lung disease, asthma, obesity, neurological problems, HIV, cancer, or tuberculosis (22).

139

# 140 **Definitions and operationalization of variables**

141 The seroprevalence of SARS-CoV-2 was determined by dividing the number of participants who 142 tested positive for IgG, IgM, or both in a lateral flow test by the total number of participants. The 143 variables: sex, "type of family", rooms per person, water supply and water storage were describe in 144 a previously research (12). "Latrines/don't have" and "other and restrooms," which are designated as 145 places with a toilet, sink, network connection, and drainage, are the two categories for the variable 146 for hygienic services (12). Visual examination was used to confirm the factors related to the water 147 supply, water storage, and hygiene services. A lateral flow test was declared positive when IgG, 148 IgM, or both findings were observed.

149

# 150 Statistical analysis

151 The SARS-CoV-2 seroprevalence ratios in Las Flores settlement were aimed to be estimated by 152 performing descriptive statistics and binomial family generalized linear models with a logarithmic 153 link function, while controlling for other variables, such as age, sex, type of family, water storage, 154 and basic hygienic services at home. Household clustering was accounted for by using robust 155 sandwich-type standard errors. Each variable was evaluated for inclusion in the final model using 156 the log likelihood ratio. 95% confidence intervals (CIs) were reported, and statistical significance 157 was set at P < 0.05. The seroprevalence was adjusted for the test's reported sensitivity (99.03%) and 158 specificity (98.65%). The statistical analysis was performed using Stata v 17.0 software (College 159 Station, Texas 77845, USA).

# 161 **Results**

A total of 580/781 (74.26%) individuals older than 2 years old agreed to participate. Female participants were 59.83 % (347/580). The overall participants' mean age was  $28.80\pm19.36$  years. MINSA stratification mean ages were from: 2 to 11 years (mean  $6.83\pm2.81$ ), 12 to 17 years (mean 14.53±1.81), 18 to 29 years (mean  $23.60\pm3.23$ ), 30 to 59 years (mean  $44.00\pm7.98$ ) and older than 60 years (mean  $67.84\pm6.80$ ). Most people lived in single families 391/580 (67.41 %), had access to public potable water 342/580 (58.97%) for 02-04 hours per day and 454/580 (78.28 %) had access to hygienic services.

169

# 170 Seroprevalence

Anti-SARS-CoV-2 antibodies were detected in 292/580 (50.34 %) participants: 282 IgG reactive, 8
IgM/IgG reactive, and 2 IgM reactive. After adjusting for sensitivity (99.03%) and specificity
(98.65%), the calculated adjusted seroprevalence was 50.15 % (95% CI: 45.92 - 54.40). Women
had a slightly higher adjusted seroprevalence compared to men (53.89 [95% CI: 48.48 - 59.23] vs.
45.49 [95% CI: 38.98 - 52.12], p=0.042). No other demographic characteristics were associated
with SARS-CoV-2 lateral flow test seropositivity (Table 1).

177

# Table 1. Seroprevalence adjusted for participant characteristics and associated factors from first and second COVID-19 wave.

180

As illustrated in Fig 1, the age groups with the highest prevalence of IgG seropositive were from 12

to 17 years (85.14%), from 30 to 59 years (59.80%) and older than 60 years (55.81%). On the other

hand, more than 80% of seropositive patients were asymptomatic in all age groups (Figure 2).

# 185 Fig 1. Seronegative and seropositivity from first and second COVID-19 wave.

186

# Fig 2. Symptomatic and asymptomatic cases in the seropositive population from first and second COVID-19 wave. In a bivariate analysis, symptoms such as cough (PR: 1.74; 95% CI: [1.27 - 2.38], p=0.001) and nasal congestion (PR: 0.60, 95% CI: [0.36 - 0.99], p=0.045) were associated with SARS-CoV-2

seropositivity. Both symptoms were associated with seropositivity in a multiple analysis (PR: 4.15,

193 95% CI: [1.90 - 9.07], p<0.001) and (PR: 0.41; 95% CI: [0.20 - 0.84], p=0.014) (Table 2).

194

Table 2. Self-reported symptoms seropositive and seronegative participants from first and second
COVID-19 wave.

197

# 198 **Discussion**

199 In the second wave, a higher COVID-19 prevalence was reported globally compared to the first 200 wave. In Peru, it grew by 100 percent between November 2020 (first wave) and December 2021 201 (second wave). This research group conducted two population-based studies in the Tumbes Region, 202 revealing the same trend (24.82% vs. 50.15%) (S1 Fig), contradictory to Regional directorate of 203 health Tumbes reported (6.11%) (14). This numbers were similar to reported in Italy, which had a 204 seroprevalence of over 50% in the second wave (23), and higher than Japan, which doubled its 205 caseload (24). Seroprevalence increased as more people were infected with the virus and its 206 different variants that could escape vaccination (25) and the immunity generated by contagion from 207 the asymptomatic to the uninfected (26). In addition, these variants resulted in variations in 208 transmissibility, disease severity, risk of reinfection, diagnostic failures, natural immunity, 209 vaccination efficacy, and treatment. Persistent community transmission in regions with a higher

explains this high seroprevalence (28). According to a weekly report from the INS, in Peru, at the

end of August 2021, the delta variant corresponded to 40% of the samples, gamma was 37%,

216 lambda was 17%, and the mu variant was 5% (29). In Tumbes, in the 20–30-year-old group. From

January to November 2022, omicron (n = 463) and delta (n = 125) variants were identified (30).

218

219 The delta variant generated a lower response to mRNA vaccines (Pfizer-BioNTech and Moderna 220 NIH), viral vectors (Oxford-AstraZeneca) (31), as well as inactivated viruses (Sinopharm-Beijing) 221 (32). On December 19, 2022, the coverage with three doses of vaccines in Tumbes was as follows: 222 55.1% for adolescents, 77.15% for young persons, 77.9% for adults, and 82.5% for the elderly. 223 Indicative of adequate coverage, the majority of doses were distributed by Pfizer (56%), 224 AstraZeneca (19.7%), Sinopharm (17%), and Moderna (7.2%) (33). In addition, the WHO classified 225 the omicron variant as concerning on November 26, 2021. Although the classic public health 226 restriction measures may be effective against the new variants, they are less effective in terms of 227 infectivity; on the other hand, herd immunity achieved with a previous variant might not be helpful 228 (28).

229

Seroprevalence in the second wave (53.89 [48.48-59.23]) was higher compared to other Reports of the second wave in Peru, where there were no gender differences (2,14), similar in France (Corsica) (34); our numbers were lower compared to the Democratic Republic of the Congo (74.3% vs. 68.3%; p = 0.021) (35), Kashmir, India (86.21 [85.86-86.55](36) and slightly higher compared to Delhi, India (52.42,OR 1.16[1.10-1.23],p<0.001)(37). A possible explanation for this increased seroprevalence in women is that they were the ones caring for positive cases at home (38); there are

more female health workers than male health workers (nurses, nurse technicians, and midwives)
(39); women purchase supplies in stores and markets, and this overexposure could lead to an
increase in COVID-19 infection.

239

There were many possible explanations for the only statistically significant clinical manifestations in this second wave (cough and nasal congestion): the new variants sacrificed their virulence for their infectious capacity, so we observed in the delta variant there was some variability in clinical expression compared to the original virus strain (40); people gained more knowledge about COVID-19 on the second wave, may have contributed to the increased prevalence of clinical manifestations.

246

247 One of the limitations of this research is the sample size and the fact that the study was conducted in 248 a single settlement, limiting the generalizability of the findings to other regions of Peru. The limited 249 availability of rapid tests, which have lower sensitivity and specificity compared to PCR tests; and 250 finally, the study did not collect data on participants' vaccination status; this information was 251 obtained from reports of the Ministry of Health. With persistent IgG seropositivity, it is 252 recommended that follow-up be conducted to detect COVID-19 sequelae related to the 253 presence of pulmonary lesions, mental health issues and, the implementation of an application-254 based surveillance system in our country. Many systematic reviews and meta-analyses revealed 255 that 62.2% of asymptomatic patients had tomographic abnormalities, indicating that they are a 256 potential source of transmission (41)

Our research has several implications for Peru's public health policy. First, the high seroprevalence indicates that a substantial portion of the population may already be infected, indicating the need to increase vaccine coverage. The significance of targeted vaccination campaigns to safeguard younger age groups with a higher seroprevalence is emphasized by the study's findings. Given the

higher seroprevalence in females, there may be gender-specific differences in exposure to the virusthat need further investigation.

# 263 **Conclusions**

This study shows a higher prevalence of SARS-CoV-2 antibodies after the second wave of COVID-19 in Tumbes, with a huge prevalence of IgG in individuals younger than 17 years old, more than 80% of seropositive patients were asymptomatic in all age groups. The findings suggest that a significant portion of the population was exposed to the virus and developed antibodies, highlighting the importance of continued efforts to control the spread of new variants of the virus through massive campaigns of vaccination.

270

# 271 Acknowledgments

272 We thank the villagers of AAHH Las Flores. LMM and team are grateful to all the regional 273 authorities from the County Town Hall, the Regional Directorate of Health-Tumbes V Jimenez, and 274 J Arias. We are grateful to the members of the Executive Office of Epidemiology N Julca, and L 275 Arevalo. LMM expresses gratitude to the members of the Grupo de Investigación de la Escuela de 276 Medicina. LMM would like to thanks for the aerial photography to JeanPierre. Angie Toledo is 277 doctoral student in the Epidemiological Research Doctorate at Universidad Peruana Cayetano 278 Heredia under FONDECYT/CIENCIACTIVA scholarship EF033-235-2015 and supported by 279 training grant D43 TW007393 awarded by the Fogarty International Center of the US National 280 Institutes of Health. Neither the FONDECYT/CIENCIACTIVA scholarship nor the training grant 281 D43 TW007393 contributed to the development of the present study.

# 282 Funding

This project was supported the Regional Directorate of Health from Tumbes, the RegionalGovernment, the local Government of Tumbes and Universidad Nacional de Tumbes.

# 285

# 286 **Footnotes**

- 287 The statements contained in this document are those of the authors and should not be construed as
- 288 official points of view of the Universidad Cesar Vallejo, Universidad Nacional de Tumbes, or other
- 289 organizations mentioned.
- 290

# 291 **References**

- 292
- Herrera-Añazco P, Uyen-Cateriano A, Mezones-Holguin E, Taype-Rondan A, Mayta-Tristan P,
   Malaga G, et al. Some lessons that Peru did not learn before the second wave of COVID-19.
   Int J Health Plann Manage. mayo de 2021;36(3):995-8.
- Mayta-Tristán P. Los tsunamis por Covid-19 en Perú: El primero malo, segundo peor. Revista
   del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo. julio de 2021;14(3):260-1.
- Gianella C, Gideon J, Romero MJ. What does COVID-19 tell us about the Peruvian health
   system? Canadian Journal of Development Studies / Revue canadienne d'études du
   développement. 3 de abril de 2021;42(1-2):55-67.
- Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, et al.
   Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a
   population-based study. The Lancet Global Health. 1 de julio de 2021;9(7):e925-31.
- Vargas-Herrera N, Araujo-Castillo RV, Mestanza O, Galarza M, Rojas-Serrano N, Solari-Zerpa
   L. SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high
   seroprevalence. The Lancet Regional Health Americas [Internet]. 1 de febrero de 2022
   [citado 16 de febrero de 2023];6. Disponible en:
- 308 https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(21)00108-3/fulltext
- 3096.MINSA. Vacuna COVID-19 en el Perú [Internet]. 2023. Disponible en:
- 310 https://www.minsa.gob.pe/reunis/data/vacunas-covid19.asp
- 311 7. MINSA. Covid 19 en el Perú Ministerio del Salud [Internet]. [citado 4 de julio de 2023].
  312 Disponible en: https://covid19.minsa.gob.pe/sala\_situacional.asp
- 3138.CDC PERU. Sala Covid-19, resumen de la situación actual del país. 2023 [citado 16 de junio de3142023]. SALA SITUACIONAL COVID 19. Disponible en:
- 315 https://public.tableau.com/views/SALASITUACIONALCOVID19/MODELOFINAL?:embed=y&:s
- 316 howVizHome=no&:host\_url=https%3A%2F%2Fpublic.tableau.com%2F&:embed\_code\_versio 317 n=3&:tabs=no&:toolbar=ves&:animate\_transition=ves&:display\_static\_image=no&:display\_s
- n=3&:tabs=no&:toolbar=yes&:animate\_transition=yes&:display\_static\_image=no&:display\_s
   pinner=no&:display\_overlay=yes&:display\_count=yes&:language=es&publish=yes&:loadOrd
- . 319 erlD=0

Gutiérrez-Tudela JW. La pandemia de la COVID-19 en el Perú: análisis epidemiológico de la segunda ola. Revista de la Sociedad Peruana de Medicina Interna. 10 de diciembre de 2021;34(4):129-129.

Lima EEC, Vilela EA, Peralta A, Rocha M, Queiroz BL, Gonzaga MR, et al. Investigating regional
 excess mortality during 2020 COVID-19 pandemic in selected Latin American countries.
 Genus. 3 de noviembre de 2021;77(1):30.

- 326 11. CDC. Disponibilidad de camas COVID-19 [Internet]. 2022 [citado 24 de abril de 2023].
  327 Disponible en: https://www.dge.gob.pe/portalnuevo/wp328 content/uploads/2022/02/camas covid 20220222.html
- Moyano LM, Toledo AK, Chirinos J, Barreto PMQV, Cavalcanti S, Gamboa R, et al. SARS-CoV-2
   seroprevalence on the north coast of Peru: A cross-sectional study after the first wave. PLOS
   Neglected Tropical Diseases. 28 de junio de 2023;17(6):e0010794.
- Moyano L, Gamboa R. Prevalencia de COVID-19 asociada con Dengue y Malaria en
  comunidades rurales y urbanas del norte de Perú. 30 de marzo de 2023 [citado 18 de junio
  de 2023]; Disponible en: https://www.protocols.io/view/prevalencia-de-covid-19-asociadacon-dengue-y-mala-cr4gv8tw
- MINSA. Situación Epidemiologia de la COVID-19 [Internet]. 2022. Disponible en:
   http://www.dge.gob.pe/portal/docs/tools/teleconferencia/2022/SE132022/03.pdf
- 15. Cisneros S, Nuntón J, Alfaro R. Asociación significativa entre el endoparasitismo intestinal
  con la edad y la presencia de ectoparásitos en Canis familiaris (Linnaeus). Manglar. 31 de
  marzo de 2020;17(1):27-32.
- 34116.Censos Nacionales 2017 XII de Población, VII de Vivienda y III de Comunidades Indígenas342[Internet]. [citado 22 de junio de 2020]. Disponible en: http://censo2017.inei.gob.pe/
- 17. Centro Medico Pampa Grande en Tumbes | MINSA [Internet]. ESTABLECIMIENTOS DE SALUD
   344 

   . [citado 11 de mayo de 2023]. Disponible en:
- 345 https://www.establecimientosdesalud.info/tumbes/centro-medico-pampa-grande-tumbes/
- Del Brutto OH, Costa AF, Mera RM, Recalde BY, Bustos JA, García HH. SARS-CoV-2 in Rural
   Latin America. A Population-based Study in Coastal Ecuador. Clin Infect Dis. 15 de julio de
   2021;73(2):314-7.
- INS. FICHA DE REPORTE DE RESULTADOS DE PRUEBA RÁPIDA. COVID-19a [Internet].
   Disponible en:
   https://web.ins.gob.pe/sites/default/files/Archivos/cnsp/coronavirus/prueba\_rapida/FICHA
- 352 %20DE%20REPORTE%20DE%20RESULTADOS%20DE%20PRUEBA%20R%C3%81PIDAv3.pdf

Moyano LM, Saito M, Montano SM, Gonzalvez G, Olaya S, Ayvar V, et al. Neurocysticercosis
as a cause of epilepsy and seizures in two community-based studies in a cysticercosisendemic region in Peru. PLoS Negl Trop Dis. febrero de 2014;8(2):e2692.

- Moyano LM, Montano SM, Vilchez Barreto P, Reto N, Larrauri L, Mori N, et al. Prevalence of
   stroke survival in rural communities living in northern Peru. PLoS One. 2021;16(7):e0254440.
- Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. COVID-19 antibody
   seroprevalence in Santa Clara County, California. Int J Epidemiol. 17 de mayo de
   2021;50(2):410-9.
- 361 23. Vicentini F, Denadai W, Gomes YM, Rose TL, Ferreira MSR, Le Moullac-Vaidye B, et al.
  362 Molecular Characterization of Noroviruses and HBGA from Infected Quilombola Children in
  363 Espirito Santo State, Brazil. PLoS One [Internet]. 22 de julio de 2013 [citado 24 de octubre de
  364 2019];8(7). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718680/
- Kinoshita R, Jung SM, Kobayashi T, Akhmetzhanov AR, Nishiura H. Epidemiology of
  coronavirus disease 2019 (COVID-19) in Japan during the first and second waves. Math Biosci
  Eng. 13 de abril de 2022;19(6):6088-101.
- 368 25. Mlcochova P, Kemp SA, Dhar MS, Papa G, Meng B, Ferreira IATM, et al. SARS-CoV-2 B.1.617.2
   369 Delta variant replication and immune evasion. Nature. noviembre de 2021;599(7883):114-9.
- 26. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
  transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 9 de abril de
  2021;372(6538):eabg3055.
- 373 27. Organización Mundial de la Salud. Orientaciones para la vigilancia de las variantes del SARS374 CoV-2: orientaciones provisionales, 9 de agosto de 2021 [Internet]. Organización Mundial de
  375 la Salud; 2021 [citado 21 de marzo de 2023]. Report No.: WHO/2019-
- 376 nCoV/surveillance/variants/2021.1. Disponible en:
- 377 https://apps.who.int/iris/handle/10665/345811
- 378 28. Seguimiento de las variantes del SARS-CoV-2 [Internet]. [citado 21 de marzo de 2023].
- 379 Disponible en: https://www.who.int/es/activities/tracking-SARS-CoV-2-variants
- 380 29. INSTITUTO NACIONAL DE SALUD [Internet]. [citado 21 de marzo de 2023]. Secuenciación
   381 Genómica del virus SARS-CoV-2 en el Perú. Disponible en:
- 382 https://web.ins.gob.pe/es/covid19/secuenciamiento-sars-cov2
- 383 30. INSTITUTO NACIONAL DE SALUD [Internet]. [citado 21 de marzo de 2023]. Distribución de
   384 casos por las VOC DELTA ÓMICRON. Disponible en:
- 385https://web.ins.gob.pe/es/covid19/georreferenciacion-casos-variante-preocupacion-386variable-delta
- 387 31. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness
  388 of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine.
  389 12 de agosto de 2021;385(7):585-94.
- 390 32. China's inactivated vaccines effective against Delta variant: study [Internet]. [citado 21 de
  391 marzo de 2023]. Disponible en: http://www.news.cn/english/2021392 08/23/c\_1310144035.htm

393 394 395	33.	Reporte Regional Vacuna COVID-19 - Reporte Regional Vacuna COVID-19 - Diresa Tumbes [Internet]. [citado 21 de marzo de 2023]. Disponible en: https://www.diresatumbes.gob.pe/index.php/covid-19/reporte-regional-vacuna-covid-19
396 397 398	34.	Frontiers   Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People [Internet]. [citado 20 de junio de 2023]. Disponible en: https://www.frontiersin.org/articles/10.3389/fpubh.2021.715192/full
399 400 401 402	35.	Munyeku-Bazitama Y, Folefack GT, Yambayamba MK, Tshiminyi PM, Kazenza BM, Otshudiema JO, et al. High SARS-CoV-2 Seroprevalence after Second COVID-19 Wave (October 2020–April 2021), Democratic Republic of the Congo. Emerg Infect Dis. enero de 2023;29(1):89-97.
403 404 405 406 407	36.	Lone KS, Khan SMS, Qurieshi MA, Majid S, Pandit MI, Haq I, et al. Seroprevalence of SARS- CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India. Frontiers in Public Health [Internet]. 2022 [citado 20 de junio de 2023];10. Disponible en: https://www.frontiersin.org/articles/10.3389/fpubh.2022.967447
408 409 410 411	37.	Sharma N, Sharma P, Basu S, Bakshi R, Gupta E, Agarwal R, et al. Second Wave of the COVID- 19 Pandemic in Delhi, India: High Seroprevalence Not a Deterrent? Cureus [Internet]. octubre de 2021 [citado 20 de junio de 2023];13(10). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8609204/
412 413 414	38.	Hossain MI, Parvin S, Islam MS, Alam MJ, Podder S, Datta R, et al. Demographic profile and outcome of patients admitted to a COVID dedicated hospital in Bangladesh during the second wave. Medicine (Baltimore). 17 de septiembre de 2021;100(37):e27281.
415 416 417 418 419 420	39.	Romero Ramos CW, Mamani-Urrutia V, Bustamante-López A, Ubillus Arriola G, Tello D. MP, Castillo Díaz ME, et al. Prevalencia y factores de riesgo asociados a infección por virus SARS- CoV-2 en trabajadores del Instituto Nacional de Salud del Niño de Perú, abril 2020 a marzo 2021. Horizonte Médico (Lima) [Internet]. enero de 2023 [citado 20 de junio de 2023];23(1). Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_abstract&pid=S1727- 558X2023000100003&lng=es&nrm=iso&tlng=es
421 422 423	40.	Thakur V, Bhola S, Thakur P, Patel SKS, Kulshrestha S, Ratho RK, et al. Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe. Infection. 1 de abril de 2022;50(2):309-25.
424 425 426	41.	Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients as a source of COVID-19 infections: A systematic review and meta-analysis. Int J Infect Dis. septiembre de 2020;98:180-6.
427	~	

## **Supporting information** 428

429

430 S1 Data. Excel spreadsheet containing, in separate sheets, the underlying data used for the

statistical analysis and description of variables. 431

- 432 S1 Text. Adult informed consent for study participation approved by the institutional review
- 433 boards of Universidad Peruana Cayetano Heredia.
- 434 S2 Text. Parent-signed informed consent for minor study participation approved by the
- 435 institutional review boards of Universidad Peruana Cayetano Heredia.
- 436 S1 Fig. Enrollment and seroprevalence flowchart of the first and second wave of COVID-19 in two
- 437 Tumbes settlements. Created with BioRender.com

## Enrolment and seroprevalence flowchart of the first and second wave of COVID 19 in two Tumbes settlements

